Spinal Anaesthesia With Levobupivacaine 0.5% and Ropivacaine 0.75% for Lower Limb Orthopaedic Surgery

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the effects of two intrathecally administered drugs:0.5% levobupivacaine and0.75%Ropivacaine in spinal anesthesia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Levobupivacaine, Ropivacaine and Bupivacaine in Epidural Anaesthesia

NCT02513433

Pain Insensitivity, Congenital

COMPLETED NA

Ropivacaine Versus Bupivacaine for Spinal Anaesthesia in Patients Undergoing Unilateral Lower Limb Surgery

NCT00358280

Anesthesia,Spinal

COMPLETED PHASE3

Local Infiltration Analgesia in Major Spine Surgery With Ropivacaine Versus Placebo

NCT00771459

Pain, Postoperative

COMPLETED PHASE4

A Randomised Comparison on the Dose Requirement Between, Levobupivacaine, Ropivacaine and Bupivacaine in Intrathecal Anaesthesia

NCT00636974

Anesthesia, Conduction Surgery

COMPLETED NA

Clinical Characteristics of Spinal Levobupivacaine: Hyperbaric Compared With Isobaric Solution

NCT01349751

Observation of Neuromuscular Block Disease (or Disorder); Gynecological

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bupivacaine is a highly cardiotoxic drug and also produces prolonged motor blockade.The newer drugs levobupivacaine and ropivacaine being comparatively less cardio and neurotoxic are preferred now a days.So, we conducted this prospective, randomized double blind study with an aim of comparing the efficacy and characteristics of these drugs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lower Limb Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Levobupivacaine 0.5%

intrathecal administration of 15 mg of Levobupivacaine 0.5%

Group Type ACTIVE_COMPARATOR

Levobupivacaine

Intervention Type DRUG

Comparison of Equipotent doses

Ropivacaine 0.75%

intrathecal administration of 22.5 mg of Ropivacaine 0.75%

Group Type ACTIVE_COMPARATOR

Ropivacaine

Intervention Type DRUG

Comparison of equipotent doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levobupivacaine

Comparison of Equipotent doses

Intervention Type DRUG

Ropivacaine

Comparison of equipotent doses

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chirocaine Naropin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. American Society of Anesthesiologists (ASA) class I \& II patients of either sex
2. Age between 18-60 years

Exclusion Criteria

1. Patient's refusal.
2. Patients who have contraindications to spinal anaesthesia / Local anaesthetic drugs.
3. Patients having h/o diabetes, neurological and musculoskeletal diseases.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No